Fondation Rothschild - service de neurologie
Welcome,         Profile    Billing    Logout  
 0 Trials 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BENSA, Caroline
TWINS, NCT06663189: Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over ( : Therapies Withdrawal IN Relapsing Multiple Sclerosis)

Not yet recruiting
3
200
Europe
treatment withdrawal, Usual DMT continuation, MRI, Quality of Life questionnaires, Disability evaluation tests
University Hospital, Strasbourg, France, Ministry of Health, France
Relapsing-remitting Multiple Sclerosis (RRMS)
01/27
06/29
BABYZUMAB-2, NCT05209815: Safety of Exposure to Natalizumab During Pregnancy

Completed
N/A
68
Europe, RoW
Questionnaire
University Hospital, Bordeaux, Biogen
Multiple Sclerosis
12/23
12/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BENSA, Caroline
TWINS, NCT06663189: Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over ( : Therapies Withdrawal IN Relapsing Multiple Sclerosis)

Not yet recruiting
3
200
Europe
treatment withdrawal, Usual DMT continuation, MRI, Quality of Life questionnaires, Disability evaluation tests
University Hospital, Strasbourg, France, Ministry of Health, France
Relapsing-remitting Multiple Sclerosis (RRMS)
01/27
06/29
BABYZUMAB-2, NCT05209815: Safety of Exposure to Natalizumab During Pregnancy

Completed
N/A
68
Europe, RoW
Questionnaire
University Hospital, Bordeaux, Biogen
Multiple Sclerosis
12/23
12/23

Download Options